Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2025)

Historic Operating Leases for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Q3 2025 value amounting to $54.8 million.

  • Enanta Pharmaceuticals' Operating Leases rose 150.9% to $54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 150.9%. This contributed to the annual value of $54.8 million for FY2025, which is 150.9% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Operating Leases stood at $54.8 million for Q3 2025, which was up 150.9% from $55.7 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Operating Leases' 5-year high stood at $56.5 million during Q1 2025, with a 5-year trough of $1.1 million in Q3 2021.
  • In the last 5 years, Enanta Pharmaceuticals' Operating Leases had a median value of $22.3 million in 2023 and averaged $29.4 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Operating Leases plummeted by 7066.18% in 2021 and then soared by 188685.61% in 2022.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Operating Leases stood at $16.0 million in 2021, then soared by 36.98% to $21.9 million in 2022, then dropped by 6.11% to $20.5 million in 2023, then soared by 175.06% to $56.5 million in 2024, then fell by 3.0% to $54.8 million in 2025.
  • Its Operating Leases was $54.8 million in Q3 2025, compared to $55.7 million in Q2 2025 and $56.5 million in Q1 2025.